| MicroRNA in disease regulation | Lifetime | 188 | CN 61 | 99.19 |
| Circular RNAs in diseases | Lifetime | 95 | CN 50 | 99.17 |
| Cancer-related molecular mechanisms research | Lifetime | 261 | CN 119 | 98.98 |
| Molecular Biology Techniques and Applications | Lifetime | 258 | CN 11 | 97.81 |
| Cancer Mechanisms and Therapy | Lifetime | 289 | CN 40 | 96.99 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 275 | CN 39 | 94.76 |
| Ferroptosis and cancer prognosis | Lifetime | 621 | CN 343 | 94.28 |
| Forensic and Genetic Research | Lifetime | 406 | CN 25 | 94.58 |
| GDF15 and Related Biomarkers | Lifetime | 171 | CN 10 | 91.12 |
| Inflammasome and immune disorders | Lifetime | 948 | CN 109 | 92.96 |
| Saffron Plant Research Studies | Lifetime | 713 | CN 100 | 66.90 |
| Molecular Biology Techniques and Applications | 2021-2025 | 1 | CN 1 | 99.07 |
| RNA modifications and cancer | 2021-2025 | 146 | CN 97 | 98.46 |
| Cancer-related molecular mechanisms research | 2021-2025 | 133 | CN 100 | 98.65 |
| Immune cells in cancer | 2021-2025 | 95 | CN 55 | 97.63 |
| Circular RNAs in diseases | 2021-2025 | 73 | CN 54 | 98.03 |
| Epigenetics and DNA Methylation | 2021-2025 | 181 | CN 74 | 96.48 |
| Immune Cell Function and Interaction | 2021-2025 | 222 | CN 51 | 96.68 |
| MicroRNA in disease regulation | 2021-2025 | 184 | CN 119 | 97.53 |
| Cancer-related gene regulation | 2021-2025 | 80 | CN 52 | 94.85 |
| Forensic and Genetic Research | 2021-2025 | 37 | CN 7 | 95.63 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 615 | CN 116 | 97.65 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 607 | CN 78 | 97.32 |
| Ferroptosis and cancer prognosis | 2021-2025 | 370 | CN 304 | 94.85 |
| interferon and immune responses | 2021-2025 | 199 | CN 108 | 92.19 |
| Immune Response and Inflammation | 2021-2025 | 188 | CN 73 | 90.10 |
| RNA Research and Splicing | 2021-2025 | 520 | CN 150 | 91.09 |
| RNA and protein synthesis mechanisms | 2021-2025 | 445 | CN 87 | 92.15 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 144 | CN 33 | 89.09 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 314 | CN 28 | 88.02 |
| Anesthesia and Pain Management | 2021-2025 | 598 | CN 72 | 88.94 |
| Inflammasome and immune disorders | 2021-2025 | 528 | CN 254 | 87.34 |
| Congenital heart defects research | 2021-2025 | 316 | CN 37 | 84.77 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 638 | CN 113 | 85.29 |
| Genetic diversity and population structure | 2021-2025 | 626 | CN 81 | 87.00 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 809 | CN 174 | 85.32 |
| Nausea and vomiting management | 2021-2025 | 277 | CN 59 | 79.08 |
| Lipid metabolism and disorders | 2021-2025 | 307 | CN 64 | 78.25 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 847 | CN 119 | 75.43 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 440 | CN 147 | 71.16 |
| Cancer Mechanisms and Therapy | 2021-2025 | 895 | CN 401 | 72.64 |
| melanin and skin pigmentation | 2021-2025 | 687 | CN 184 | 72.41 |
| Apelin-related biomedical research | 2021-2025 | 162 | CN 29 | 71.71 |
| Galectins and Cancer Biology | 2021-2025 | 673 | CN 184 | 70.14 |
| Hereditary Neurological Disorders | 2021-2025 | 605 | CN 45 | 64.66 |
| Telomeres, Telomerase, and Senescence | 2021-2025 | 811 | CN 107 | 62.96 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 956 | CN 479 | 62.84 |
| Acne and Rosacea Treatments and Effects | 2021-2025 | 704 | CN 151 | 63.26 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 558 | CN 91 | 58.99 |
| Traditional Chinese Medicine Studies | 2021-2025 | 724 | CN 531 | 58.55 |
| FOXO transcription factor regulation | 2021-2025 | 236 | CN 80 | 54.81 |
